Report Company Directory

TRAVIS PERKINS

• Travis Perkins: Director/PDMR Shareholding by EQS Group AG
• Travis Perkins: Director/PDMR Shareholding by EQS Group AG
• Travis Perkins: Director/PDMR Shareholding by EQS Group AG
• Travis Perkins: Final Results of Tender Offer by EQS Group AG
• Travis Perkins: Indicative Results of Tender Offer by EQS Group AG
• Travis Perkins: Publication of Notice of Annual General Meeting to be held on Wednesday, 14 May 2025 by EQS Group AG
• Travis Perkins: Director/PDMR Shareholding by EQS Group AG
• Travis Perkins: TR1 Notification of Major Share Interest by EQS Group AG
• Travis Perkins: Publication of the Annual Report and Accounts 2024 by EQS Group AG
• Travis Perkins: TR1 Notification of Major Share Interest by EQS Group AG

Travis Perkins plc

• European Morning Research Summary by Stifel
• Recovery postponed, not cancelled by Stifel
• European Morning Research Summary by Stifel
• London is losing listings - time for reform by Stifel
• European Morning Research Summary by Stifel
• FY results: cash flow highlight, subdued start to the year by Stifel
• European Morning Research Summary by Stifel
• Estimate cuts on more prudent 2026 view by Stifel
• European Morning Research Summary by Stifel
• UK building materials: more selective pre-reporting, cut Travis Perkins to Hold by Stifel

TRAWELL CO S.P.A.

• TraWell Co Conducts Sustainability Assessment With Cerved Rating Agency by BusinessWire

TRAWS PHARMA INC

• Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza by GlobeNewsWire
• Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza by GlobeNewsWire
• Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients by GlobeNewsWire
• Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients by GlobeNewsWire
• Traws Pharma Reports Third Quarter 2025 Results and Business Highlights by GlobeNewsWire
• Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 by GlobeNewsWire
• Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives by GlobeNewsWire
• Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 by GlobeNewsWire
• Traws Pharma Reports Second Quarter 2025 Results and Business Highlights by GlobeNewsWire
• Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 by GlobeNewsWire

TRB SYSTEMS INTERNATIONAL INC